The company reported a loss of 13 cents a share, which was wider than the Capital IQ Consensus Estimate of a loss of 2 cents a share. But revenues increased 20.3% year over year to $239.6 million to surpass the $221.69 consensus estimate.
BioScrip also issued full-year revenue guidance for 2014 in the range of $940 million to $980 million, which beat analysts' estimate of $922.39 million.
Must Read: Warren Buffett's 10 Favorite Growth Stocks
The stock was up 15.6% to $7.04 at 3:17 p.m.